Last reviewed · How we verify
Labetalol Injection
Labetalol Injection, marketed by Tanta University, is a well-established treatment in its class. A key strength is the protection afforded by its composition patent, which is set to expire in 2028. The primary risk lies in the potential increase in competition following the patent expiry.
At a glance
| Generic name | Labetalol Injection |
|---|---|
| Also known as | Trandate, Labipress tablets, Normodyne |
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors (PHASE2, PHASE3)
- Hypotensive Anesthesia for Orthognathic Surgery (PHASE4)
- Intravenous Labetalol Versus Hydralazine in Preeclampsia (PHASE1, PHASE2)
- Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment (NA)
- Effects Magnesium Sulfate and Labetalol Infusion on Peripheral Perfusion and Pain in Nasal Surgeries (PHASE1, PHASE2)
- Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia (PHASE2, PHASE3)
- Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke (PHASE2)
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-II (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Labetalol Injection CI brief — competitive landscape report
- Labetalol Injection updates RSS · CI watch RSS
- Tanta University portfolio CI